Start with its own history
At 24.16×, HAE is 56.4% below its 9-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
NYSE · HAEMedical - DevicesUpdated Nov 2, 2026
Haemonetics Corporation P/E ratio
Current valuation, historical context, and peer comparisons.
Current P/E ratio
24.16×
56.4% belowthe 9-observation annual average
Share price121.03
÷Earnings per share5.01
Price and EPS in quote currency. Calculation details
Investors are paying 24.16 for every 1 of reported earnings per share.
P/E over time
2017 – 2026
Annual P/ESelected-period average 55.39×
3-year average27.33×3 positive annual observations
5-year average38.57×5 positive annual observations
10-year average55.39×9 positive annual observations
Peer median · TTM42.22×5 peers with positive P/E
Historical P/E ratios
Annual period-end data · 25 observations
| Period end | P/E | Change |
|---|---|---|
| Mar 28, 2026 | 26.36× | +38.1% |
| Mar 29, 2025 | 19.09× | -47.8% |
| Mar 31, 2024 | 36.55× | +0.3% |
| Mar 31, 2023 | 36.45× | -51.0% |
| Mar 31, 2022 | 74.38× | +5.2% |
| Mar 31, 2021 | 70.71× | +7.1% |
| Mar 31, 2020 | 66.00× | -21.3% |
| Mar 31, 2019 | 83.88× | -1.4% |
View all 25 annual observations +
| Period end | P/E | Change |
|---|---|---|
| Mar 31, 2018 | 85.07× | N/M |
| Mar 31, 2017 | N/M | N/M |
| Mar 31, 2016 | N/M | N/M |
| Mar 31, 2015 | 136.12× | +184.0% |
| Mar 31, 2014 | 47.93× | -12.5% |
| Mar 31, 2013 | 54.75× | +104.3% |
| Mar 31, 2012 | 26.80× | +30.0% |
| Mar 31, 2011 | 20.61× | -17.1% |
| Mar 31, 2010 | 24.85× | +5.6% |
| Mar 31, 2009 | 23.54× | -21.0% |
| Mar 31, 2008 | 29.79× | +17.2% |
| Mar 31, 2007 | 25.41× | +29.1% |
| Mar 31, 2006 | 19.68× | -28.1% |
| Mar 31, 2005 | 27.38× | +4.5% |
| Mar 31, 2004 | 26.21× | +36.7% |
| Mar 31, 2003 | 19.17× | -31.8% |
| Mar 31, 2002 | 28.11× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
How HAE compares
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
 HAE This stockHaemonetics Corporation | 24.16× |
 XRAYDENTSPLY SIRONA Inc. | N/M |
 CONConcentra Group Holdings Parent, Inc. | 25.70× |
 WRBYWarby Parker Inc. | 382.90× |
 ITGRInteger Holdings Corporation | 42.22× |
 QDELQuidelOrtho Corporation | N/M |
 LMATLeMaitre Vascular, Inc. | 28.24× |
 BHCBausch Health Companies Inc. | N/M |
 PINCPGIM Securitized Income ETF | 59.40× |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
What does HAE’s P/E tell you?
Compare like with like
The median of the 5 positive peer ratios above is 42.22×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
Check what drives earnings
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Take HAE into your spreadsheet
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore WisesheetsQuarterly P/E · latest quarterLQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data
=WISE("HAE", "PE Ratio", "LQ")Sources & calculation methodology
Current P/E
Share price 121.03 ÷ EPS 5.01 = 24.16×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Nov 2, 2026; this is not a real-time trading quote.
History & averages
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
Data definitions and limitations
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
HAE P/E ratio: common questions
The essentials behind the numbers.
Haemonetics Corporation's current P/E is 24.16× based on the quote data last updated Nov 2, 2026. It represents the share price divided by reported earnings per share. Prices and earnings may refresh on different schedules.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.